ADIAL
Updated 502 days ago
- Age: 13 years
- ID: 51088156/4
1180 Seminole Trail, Ste 495 Charlottesville, VA 22901
Adial is a biopharmaceutical company focused on the treatment and prevention of addictions and other unmet medical needs. We are in clinical and pre-clinical stages with multiple drug candidates including a genetically targeted therapeutic drug, AD04, for Alcohol Use Disorder (AUD) in Phase 3 and through our subsidiary, Purnovate, pre-clinical candidates including candidates for non-opioid pain management, and the treatment of metastatic breast cancer... Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's..
Also known as: Adial Inc., Adial Pharma, Adial Pharmaceutical, Inc., Adial Pharmaceuticals, Adial Pharmaceuticals, Inc.